Estadístiques de NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer
Visites totals
| views | |
|---|---|
| NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer | 39 |
Visites totals per mes
| views | |
|---|---|
| July 2024 | 0 |
| August 2024 | 11 |
| September 2024 | 12 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
Visites al fitxer
| views | |
|---|---|
| Santana_jec_cell.pdf(legacy) | 3 |
| Santana_jec_cell.pdf | 2 |
Vistes principals per país
| views | |
|---|---|
| United States | 23 |
| Belgium | 5 |
| Spain | 3 |
| Australia | 2 |
| China | 2 |
| Mongolia | 2 |
| Honduras | 1 |
| Ireland | 1 |
Visites principals per ciutat
| views | |
|---|---|
| Milwaukee | 6 |
| Menlo Park | 5 |
| San Ramon | 4 |
| Barcelona | 3 |
| San Mateo | 2 |
| Sükhbaatar | 2 |
| Ann Arbor | 1 |
| Dickson | 1 |
| Las Vegas | 1 |
| Mountain View | 1 |
| Portland | 1 |
| Sacramento | 1 |